指南与共识炎症性肠病

COVID-19大流行背景下对当前ECCO/ESPGHAN儿童急性重症结肠炎管理指南的改编:RAND适当性小组

Adaptations to the current ECCO/ESPGHAN guidelines on the management of paediatric acute severe colitis in the context of the COVID-19 pandemic: a RAND appropriateness panel.
指南 / 共识 · Gut · 2020-09-01

该RAND适当性小组由14名儿童胃肠病学及儿童外科、风湿病学、呼吸和感染病学专家组成,评估COVID-19大流行期间儿童急性重症结肠炎(ASC)干预措施的适当性。小组推荐ASC患者入院时进行SARS-CoV-2拭子检测和快速生物筛查并隔离,一线使用甲泼尼龙,所有患者推荐血栓预防,二线使用英夫利西单抗不考虑SARS-CoV-2状态,因SARS-CoV-2感染推迟结肠切除术被认为不适当。

要点

  • ASC患者入院时应进行SARS-CoV-2拭子检测和快速生物筛查,并应隔离。
  • 甲泼尼龙被认为是所有ASC患者(包括有症状COVID-19者)适当的一线管理。
  • 需要二线治疗时,英夫利西单抗被认为适当,不考虑SARS-CoV-2状态。

核心结论

  • 使用RAND小组对儿童ASC指南进行的COVID-19特异性改编总体支持现有推荐,特别是使用皮质类固醇和升级至英夫利西单抗,不考虑SARS-CoV-2状态。
  • 推荐考虑常规预防性抗凝。

研究设计与样本

  • 召集了一个RAND适当性小组,包括14名儿童胃肠病学家和儿童外科、风湿病学、呼吸和感染病学专家。
  • 小组成员在COVID-19大流行背景下对ASC干预措施的适当性进行评分,结果在主持会议上讨论后进行第二次调查。

主要发现

  • 小组成员推荐ASC患者入院时进行SARS-CoV-2拭子检测和快速生物筛查,并应隔离。
  • 拭子阳性应触发与COVID-19专家的讨论。
  • 推荐在升级至二线治疗或结肠切除术前进行乙状结肠镜检查。
  • 甲泼尼龙被认为是所有患者(包括有症状COVID-19者)适当的一线管理;所有患者也推荐血栓预防。
  • 在需要二线治疗的患者中,英夫利西单抗被认为适当,不考虑SARS-CoV-2状态;因SARS-CoV-2感染推迟结肠切除术被认为不适当。

关键数值与推荐

  • 皮质类固醇在8-10周内逐渐减量被认为对所有患者适当。
  • 成功皮质类固醇救援后,硫嘌呤维持治疗在SARS-CoV-2拭子阴性患者和无症状拭子阳性患者中被评为适当,但在有症状COVID-19患者中不确定。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Paediatric acute severe colitis (ASC) management during the novel SARS-CoV-2/COVID-19 pandemic is challenging due to reliance on immunosuppression and the potential for surgery. We aimed to provide COVID-19-specific guidance using the European Crohn's and Colitis Organisation/European Society for Paediatric Gastroenterology, Hepatology and Nutrition guidelines for comparison. DESIGN: We convened a RAND appropriateness panel comprising 14 paediatric gastroenterologists and paediatric experts in surgery, rheumatology, respiratory and infectious diseases. Panellists rated the appropriateness of interventions for ASC in the context of the COVID-19 pandemic. Results were discussed at a moderated meeting prior to a second survey. RESULTS: Panellists recommended patients with ASC have a SARS-CoV-2 swab and expedited biological screening on admission and should be isolated. A positive swab should trigger discussion with a COVID-19 specialist. Sigmoidoscopy was recommended prior to escalation to second-line therapy or colectomy. Methylprednisolone was considered appropriate first-line management in all, including those with symptomatic COVID-19. Thromboprophylaxis was also recommended in all. In patients requiring second-line therapy, infliximab was considered appropriate irrespective of SARS-CoV-2 status. Delaying colectomy due to SARS-CoV-2 infection was considered inappropriate. Corticosteroid tapering over 8-10 weeks was deemed appropriate for all. After successful corticosteroid rescue, thiopurine maintenance was rated appropriate in patients with negative SARS-CoV-2 swab and asymptomatic patients with positive swab but uncertain in symptomatic COVID-19. CONCLUSION: Our COVID-19-specific adaptations to paediatric ASC guidelines using a RAND panel generally support existing recommendations, particularly the use of corticosteroids and escalation to infliximab, irrespective of SARS-CoV-2 status. Consideration of routine prophylactic anticoagulation was recommended.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Hansen R, Meade S, Beattie RM, et al. Adaptations to the current ECCO/ESPGHAN guidelines on the management of paediatric acute severe colitis in the context of the COVID-19 pandemic: a RAND appropriateness panel. Gut. 2020. PMID: 32873696. doi:10.1136/gutjnl-2020-322449

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。